Uncover key drivers, emerging technologies, and competitive movements shaping the claudin 18.2 targeted therapy market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Claudin 18.2 Targeted Therapy Market between 2026 and 2030?

The claudin 18.2 targeted therapy market has seen rapid expansion in its size over recent years. This market is projected to expand from $1.6 billion in 2025 to $1.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 23.7%. Factors contributing to its historical growth include the rising incidence of gastric and gastrointestinal cancers, progress in antibody engineering technologies, an increase in oncology-focused clinical trials, greater investments in targeted cancer treatments, and a deeper comprehension of claudin protein biology.

The claudin 18.2 targeted therapy market is anticipated to experience substantial growth in the coming years, with its size projected to reach $4.61 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.5%. This expansion during the forecast period is primarily driven by increasing regulatory approvals for targeted oncology drugs, a rising demand for personalized cancer treatment, the broadening of combination therapy approaches, growing investments in the oncology pipeline, and the increasing adoption of precision diagnostics. Significant trends foreseen in this period include an enhanced focus on biomarker-driven oncology therapies, the accelerating development of claudin 18.2 monoclonal antibodies, the growing expansion of indication-specific targeted treatments, improved integration of companion diagnostics, and an increase in strategic collaborations within precision oncology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Claudin 18.2 Targeted Therapy Market?

An increase in gastrointestinal cancer cases is projected to drive the expansion of the claudin 18.2 targeted therapy market in the future. Gastrointestinal (GI) cancers are defined as malignant growths originating anywhere within the digestive system, spanning from the esophagus to the rectum. This surge in GI cancers is primarily attributed to poor dietary habits, specifically diets high in processed foods and lacking fiber, which fosters gut inflammation and elevates the likelihood of cancer. Claudin 18.2 targeted therapy offers a solution for gastrointestinal cancers by precisely focusing on the Claudin 18.2 protein, which is excessively present on cancerous cells. This mechanism allows drugs or antibodies to eradicate malignant cells while preserving healthy tissues, thereby enhancing the efficacy of treatment. As an illustration, in June 2025, data from the US-based public health agency, the Centers for Disease Control and Prevention (CDC), indicated that 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths due to colorectal cancer were recorded in 2023. Consequently, the growing frequency of gastrointestinal cancers is fueling the expansion of the Claudin 18.2 targeted therapy market.

How Is The Claudin 18.2 Targeted Therapy Market Organized Into Various Segments?

The claudin 18.2 targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types

2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications

3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies

2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies

3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates

4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

Which Innovation Trends Are Advancing Developments Within The Claudin 18.2 Targeted Therapy Market?

Major companies within the claudin 18.2 targeted therapy market are concentrating on developing innovative solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and improve treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to bind precisely to a single target, like a protein on cancer cell surfaces, assisting the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for treating patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, thereby activating the immune system to destroy cancer cells. Clinical trials indicated it significantly improves progression-free and overall survival when combined with chemotherapy, compared to chemotherapy alone. This innovative therapy provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, addressing an unmet need in aggressive gastric cancer.

Who Are The Top-Performing Companies In The Claudin 18.2 Targeted Therapy Market In Recent Years?

Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Claudin 18.2 Targeted Therapy Market?

Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Claudin 18.2 Targeted Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28169&type=smp

Browse Through More Reports Similar to the Global Claudin 18.2 Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Coronavirus Current Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

Next Generation Antibody Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.